Tamika Chester, NP
Nurse Practitioner · Warner Robins, GANPI 1053770669
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.1%), speaking fees and education — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by AbbVie at 57.9% of the total. 2025 is the largest year on record at $7,031, 4.4 times the $1,585 reported in 2021. Among nurse practitioner clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 534 payments — averaging $35.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$11K
- Regeneron Healthcare Solutions, Inc.$2K
- Sanofi$833
- Johnson & Johnson$831
- Novartis$715
- Incyte Corporation$648
- plus $3K from 15 others
What the payments were for
- Speaking & faculty fees$8,35044%
- Travel & lodging$1921%
- Food & beverage$9,47650%
- Education$9095%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 130 | $10,965 |
| Regeneron Healthcare Solutions, Inc. | 81 | $1,942 |
| Sanofi | 30 | $833 |
| Johnson & Johnson | 34 | $831 |
| Novartis | 53 | $715 |
| Incyte Corporation | 28 | $648 |
| E.r. Squibb & Sons, L.L.C. | 35 | $625 |
| Pfizer | 47 | $559 |
| Sun Pharmaceutical Industries Inc. | 15 | $383 |
| Amgen | 9 | $279 |
| UCB, Inc. | 20 | $205 |
| Lilly USA, LLC | 11 | $195 |
| LEO Pharma Inc. | 7 | $137 |
| Mayne Pharma Commercial LLC | 11 | $135 |
| Dermavant Sciences, Inc. | 7 | $122 |
| Galderma Laboratories, L.p. | 6 | $111 |
| Arcutis Biotherapeutics, Inc. | 4 | $90 |
| Sanofi-aventis U.S. LLC | 1 | $65 |
| Organon | 3 | $43 |
| Almirall LLC | 1 | $26 |
| Boehringer Ingelheim | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,927 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 126 | $496,292 |
| Humira(Cf) PenAdalimumab | 43 | $485,692 |
| Cosentyx Unoready PenSecukinumab | 22 | $194,923 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 13 | $93,777 |
| RinvoqUpadacitinib | 13 | $92,584 |
| AdbryTralokinumab-Ldrm | 11 | $39,745 |
| Clobetasol Propionate | 145 | $6,677 |
| Triamcinolone Acetonide | 531 | $6,151 |
| Clindamycin Phosphate | 185 | $6,090 |
| Betamethasone Dipropionate | 88 | $5,424 |
| Ketoconazole | 283 | $4,075 |
| Fluocinonide | 91 | $3,935 |
| Doxycycline Hyclate | 118 | $3,733 |
| Pimecrolimus | 23 | $1,966 |
| Tacrolimus | 26 | $1,864 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $10,965 | $92,58413 claims |
| LEO Pharma Inc.Adbry | $137 | $39,74511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,328 nurse practitioner providers in Georgia.
Other nurse practitioner in Warner Robins
- Victor CzerkasijDalton$505K
- Kennon Mc CollumStockbridge$364K
- Tajuana BradleyJohns Creek$256K
- Jessica AdkinsSavannah$226K
- Janice McAlisterAtlanta$221K
- Laura ElledgeAtlanta$177K
- Afsha HussainiKennesaw$122K
- Elizabeth TyeAlbany$78K
- Luis PoloSavannah$70K
- Karen BauerDecatur$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.